Home › Chronic Myeloid Leukemia › Wisconsin › Madison
Chronic Myeloid Leukemia clinical trials in Madison, WI
3 studies for Chronic Myeloid Leukemia are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
RecruitingPhase 1
- University of Wisconsin - Madison, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- University of Wisconsin - Madison, Madison
About Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It usually affects older adults. Learn about symptoms, genetics, and treatment.
More about Chronic Myeloid Leukemia on MedlinePlus
Chronic Myeloid Leukemia trials in other cities
- Houston, TX18 studies
- Seattle, WA11 studies
- New York City, NY10 studies
- Portland, OR7 studies
- Baldwin Park, CA7 studies
- Chicago, IL7 studies
- Detroit, MI6 studies
- Birmingham, AL6 studies
- Philadelphia, PA6 studies
- St. Louis, MO6 studies
- Milwaukee, WI5 studies
- Nashville, TN5 studies
Other studies in Madison
- Prostate Cancer29 studies
- Breast Cancer22 studies
- Colorectal Cancer22 studies
- Metastatic Cancer20 studies
- Acute Myeloid Leukemia17 studies
- Melanoma15 studies
- Non-Small Cell Lung Cancer14 studies
- Cancer (all types)14 studies
- Ovarian Cancer14 studies
- Lung Cancer11 studies
- Stomach Cancer11 studies
- Pancreatic Cancer9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.